Matthew Cortese, MD, MPH

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Abbvie, Inc.
    Topic:
    CLL/SLL, Lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astra Zeneca, Inc
    Topic:
    CLL/SLL, Lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    ADC Therapeutics, Inc
    Topic:
    CLL/SLL, Lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Precision Oncology
    Topic:
    CLL/SLL, Lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Secura Bio, Inc
    Topic:
    CLL/SLL, Lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Cellectar Biosciences
    Topic:
    LPL/WM, CNS lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Synthekine
    Topic:
    CLL/SLL, Lymphomas
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Curio Life Sciences
    Topic:
    Hodgkin Lymphoma
    Date added:
    01/26/2024
    Date updated:
    03/06/2024
Return to Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting